Mabion SA - Product Pipeline Review - 2015

Published: Jul, 2015 | Pages: 27 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Mabion SA - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Mabion SA - Product Pipeline Review - 2015', provides an overview of the Mabion SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Mabion SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Mabion SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Mabion SA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Mabion SA's pipeline products

Reasons to buy

- Evaluate Mabion SA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Mabion SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Mabion SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Mabion SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mabion SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Mabion SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Mabion SA Snapshot 5
Mabion SA Overview 5
Key Information 5
Key Facts 5
Mabion SA - Research and Development Overview 6
Key Therapeutic Areas 6
Mabion SA - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Mabion SA - Pipeline Products Glance 11
Mabion SA - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Mabion SA - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Mabion SA - Drug Profiles 13
rituximab biosimilar 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
adalimumab biosimilar 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
bevacizumab biosimilar 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
cetuximab biosimilar 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
ranibizumab biosimilar 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
trastuzumab biosimilar 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Mabion SA - Pipeline Analysis 20
Mabion SA - Pipeline Products by Target 20
Mabion SA - Pipeline Products by Route of Administration 21
Mabion SA - Pipeline Products by Molecule Type 22
Mabion SA - Pipeline Products by Mechanism of Action 23
Mabion SA - Recent Pipeline Updates 24
Mabion SA - Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 26
Disclaimer 27

List of Tables

Mabion SA, Key Information 5
Mabion SA, Key Facts 5
Mabion SA - Pipeline by Indication, 2015 7
Mabion SA - Pipeline by Stage of Development, 2015 9
Mabion SA - Monotherapy Products in Pipeline, 2015 10
Mabion SA - Phase III, 2015 11
Mabion SA - Preclinical, 2015 12
Mabion SA - Pipeline by Target, 2015 20
Mabion SA - Pipeline by Route of Administration, 2015 21
Mabion SA - Pipeline by Molecule Type, 2015 22
Mabion SA - Pipeline Products by Mechanism of Action, 2015 23
Mabion SA - Recent Pipeline Updates, 2015 24
Mabion SA, Other Locations 25